The Role of Smoking History in the Efficacy of Neoadjuvant and Perioperative Therapy for Lung Cancer

Lung cancer is one of the leading causes of cancer-related mortality worldwide, and neoadjuvant therapy has become a cornerstone in the management of resectable non-small-cell lung cancer (NSCLC). Growing evidence suggests that smoking history is an important clinical and biological factor that influences response to neoadjuvant treatment. This review synthesizes epidemiologic, translational, and clinical evidence, including findings from landmark clinical trials. It aims to evaluate the efficacy of neoadjuvant chemotherapy, immunotherapy, targeted therapy, and multimodal treatment strategies according to smoking status. Furthermore, this review examines the molecular and immunologic mechanisms underlying the differential treatment responses observed among current, former, and never-smokers. Ultimately, there is an increasing need to conduct prospective smoking-stratified studies and integrate smoking history into medical practice to develop more personalized neoadjuvant therapies for patients with lung cancer.

Authors

Publication Details

Journal
Cancers
Published
2026-11-18
DOI
https://doi.org/10.3390/cancers18223691
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Role of Smoking History in the Efficacy of Neoadjuvant and Perioperative Therapy for Lung Cancer

Erminia Massarelli, Aishani Sivasai Gargapati, Kelby Nixon
Cancers
Lung Cancer Diagnosis and Treatment
article

The Role of Smoking History in the Efficacy of Neoadjuvant and Perioperative Therapy for Lung Cancer

Erminia Massarelli, Aishani Sivasai Gargapati, Kelby Nixon
article en

Abstract

Lung cancer is one of the leading causes of cancer-related mortality worldwide, and neoadjuvant therapy has become a cornerstone in the management of resectable non-small-cell lung cancer (NSCLC). Growing evidence suggests that smoking history is an important clinical and biological factor that influences response to neoadjuvant treatment. This review synthesizes epidemiologic, translational, and clinical evidence, including findings from landmark clinical trials. It aims to evaluate the efficacy of neoadjuvant chemotherapy, immunotherapy, targeted therapy, and multimodal treatment strategies according to smoking status. Furthermore, this review examines the molecular and immunologic mechanisms underlying the differential treatment responses observed among current, former, and never-smokers. Ultimately, there is an increasing need to conduct prospective smoking-stratified studies and integrate smoking history into medical practice to develop more personalized neoadjuvant therapies for patients with lung cancer.

CancersVol. 18(22)
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon